AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02920892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language Intervention
Description: All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children.
Study NCT02920892 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Language Intervention
Description: All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children.
Study NCT02107833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPRX-106
Study NCT02356913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Study NCT02356913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
Study NCT02519023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
Study NCT02519023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
Study NCT02519023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
Study NCT04486235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief waiting room pamphlet
Description: An experiential pamphlet including brief assessment questions and recommended questions for the participant to ask their physician based on their responses. Areas covered in the pamphlet include patients' knowledge of weight status and implications of weight, confidence in physicians' abilities to treat weight, stage of change for weight-related behaviors, and comfort in discussing their weight.
Study NCT00804700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active teaching in synchronous listening to music while exercising
Description: Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
Study NCT00804700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active teaching in synchronous listening to music while exercising
Description: Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
Study NCT00881517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCMV-specific hyperimmune globulin (Cytotect®)
Description: 100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
Study NCT00881517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic solution of sodium chloride (placebo)
Description: 2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
Study NCT00778778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefprozil 500mg tablets
Study NCT00778778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefprozil 500mg tablets
Study NCT02604381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract
Study NCT02604381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05865626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOT with and without cash incentive
Description: Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination
Study NCT03788174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
Study NCT03788174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study NCT03326388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib Intermittent Dosing
Study NCT01788566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV
Study NCT01788566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT01788566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV
Study NCT01667289 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Description: Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
Study NCT01667289 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy alone
Description: Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
Study NCT01667289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation
Description: Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy
Study NCT01379183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: 200 mg suspension
Study NCT01379183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg suspension
Study NCT01379183 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
Study NCT01379183 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
Study NCT01379183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barium Sulfate Solution
Description: Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
Study NCT01379183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Barium Sulfate Solution
Description: Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
Study NCT03744728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Accelerate PhenoTest™ BC kit
Description: The Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture
Study NCT03744728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
Study NCT03652012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS in a non-invasive brain stimulation technique. In this study, we will use TMS to excite brain tissue in the motor cortex and measure the subsequent motor response in the hand. This 'intervention' will be the same in both cohorts, as we are interested in how this motor response to TMS may vary across two distinct cohorts.
Study NCT03652012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS in a non-invasive brain stimulation technique. In this study, we will use TMS to excite brain tissue in the motor cortex and measure the subsequent motor response in the hand. This 'intervention' will be the same in both cohorts, as we are interested in how this motor response to TMS may vary across two distinct cohorts.
Study NCT02530021 — intervention group
Intervention type: OTHER
Intervention: Heart rate monitor
Description: One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
Study NCT03167333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: The amount of PPR was about 4-5 cc
Study NCT03167333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: HA was 2.5cc
Study NCT02867735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LKA651
Description: Interventional
Study NCT02867735 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Study NCT03274908 — intervention group
Intervention type: OTHER
Intervention: regular medical treatment
Description: regular medical treatment
Study NCT02644759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
Study NCT03258307 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative level
Description: Blood sample
Study NCT03258307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative level
Description: Blood sample
Study NCT03408197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyWarm
Description: Perioperative warming with EasyWarm to prevent inadvertent hypothermia during anaesthesia
Study NCT03408197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BairHugger
Description: Perioperative warming with BairHugger to prevent inadvertent hypothermia during anaesthesia
Study NCT04337424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling salivary
Description: Collection of 1 to 2 ml of saliva
Study NCT04178798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 MG Oral Capsule
Description: Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
Study NCT02631096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB-001467
Description: An IV infusion of ARB-001467
Study NCT02631096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An IV infusion of placebo
Study NCT02960217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX007
Description: liquid for oral (PO) administration
Study NCT02960217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: liquid safflower oil for PO administration
Study NCT04404868 — intervention group
Intervention type: OTHER
Intervention: Normal clinical practice
Description: There are no experimental interventions. The procedures are in line with normal clinical practice.
Study NCT04335617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMPF (Micronized purified Flavonoid-Fraction)
Description: 500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
Study NCT04335617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily
Study NCT01679496 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food items
Description: Food items with different fatty acid composition
Study NCT01679496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food items
Description: Food items with different fatty acid composition
Study NCT04477408 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: plantar sensory exercise group
Description: plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)
Study NCT05035758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: In the beginning, the patients from group B will receive an introductory lecture about transcendental meditation (TM) which includes general information, the procedure itself and other techniques of relaxation and personal development.~In this first session the method is learned by practice, in the following 3 meetings additional instructions are given about the correct practice of the TM technique; TM is practiced twice a day for 20 minutes. The method is easy to learn and effortless. To guarantee the right performance of TM by the patients, there will be two group meetings per week and one individual personal meeting with the TM teacher.After discharge from the rehabilitation program (after 4 weeks) there will be meetings offered according to the patients need. This will then be arranged individually.
Study NCT05035758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: In addition to the standard rehabilitation exercise training, the patients in this group will receive a 20-minute workshop where they learn how to do the yoga exercise. The initial yoga workshop will be held by Dr. Gilda Wüst who is a yoga expert with a lot of experience based in St. Radegund.~After this, yoga sessions will be included (additionally to the regular/standard exercise) into their daily timetable. Two yoga sessions will be done every day, one in the morning (6:30-6:50) and one in the evening (16:30-16:50) and will last for about 20 minutes.
Study NCT00660192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
Study NCT00660192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
Study NCT02866058 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean Section
Study NCT01775774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Description: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
Study NCT02787395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shoulder dislocation self reduction
Description: shoulder dislocation self reduction using one of three methods in the study
Study NCT00271375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring For You, Caring For Me
Description: 5-week Education and Support Program for Caregivers of older adults.
Study NCT00271375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring for you, caring for me + social worker
Description: 5-week Education and Support Program for Caregivers of older adults.+ augmentation with social worker
Study NCT00271375 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group usual care
Study NCT02714192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise stress test (BCTT)
Description: Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
Study NCT04559854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful After Cancer
Description: The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.
Study NCT00240058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regional phenylephrine arterial infusion, Nitric Oxide Clamp
Study NCT01577017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
Study NCT02483806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0->5->10, 0->10->5, 5->10->0, 5->0->10, 10->5->0, 10->0->5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
Study NCT04369313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: umbilical cord clamping more than 30 seconds after birth